三鑫醫療(300453.SZ):全資子公司四川威力生取得醫療器械生產許可證
格隆匯4月30日丨三鑫醫療(300453.SZ)公佈,公司全資子公司四川威力生醫療科技有限公司(簡稱“四川威力生”)近日取得四川省藥品監督管理局頒發的《醫療器械生產許可證》。生產範圍包括2002分類目錄Ⅲ類:6845-7-透析粉、透析液;2017分類目錄Ⅲ類:10-04-血液淨化及腹膜透析器具。
四川威力生已於2021年3月取得國家藥品監督管理局頒發的《醫療器械註冊證》。該次取得《醫療器械生產許可證》後,四川威力生將正式開始透析液的生產。
四川威力生此次取得《醫療器械生產許可證》,有利於進一步提升公司血液透析系列產品產能、完善血液透析系列產品市場佈局,有效降低透析系列產品特別是透析液產品的經營成本,提升公司血液透析系列產品綜合效益及公司的競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.